Emylcamate

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Emylcamate
Emylcamate.svg
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.001.002
Chemical and physical data
Formula C7H15NO2
Molar mass 145.20 g·mol−1
3D model (Jmol)
  (verify)

Emylcamate (marketed as Striatran by Merck) is an anxiolytic and muscle relaxant. It was patented in the US in 1961 (US Patent 2,972,564) and advertised for the treatment of anxiety and tension. It was claimed to be superior to meprobamate, which was the market leader at the time. It is no longer prescribed.

A study of the drug's effects in mice was done in 1959. It concluded that at 50 mg/kg emylcamate gave a 63% decrease in motor activity compared to meprobamate's 32% decrease, a doubling in effective potency. The therapeutic index in mice was also established:

Meprobamate Emylcamate Effect
175 123 ED50 (mg/kg)
600 550 LD50 (mg/kg)
3.4 4.4 Therapeutic index

Emylcamate also has a faster intra-parenteral onset then meprobabamate, 3 minutes compared to 35. [1]

References[edit]

  1. ^ Melander, B. (1959). "Emylcamate, A Potent Tranquillizing Relaxant". Journal of Medicinal and Pharmaceutical Chemistry. 1 (5): 443–457. doi:10.1021/jm50006a003.